We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03616860
Recruitment Status : Active, not recruiting
First Posted : August 6, 2018
Last Update Posted : January 4, 2023
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety of blood-brain barrier (BBB) disruption in adult patients with a first presentation of a glioblastoma (GBM) following a maximal safe surgical resection and standard chemo-radiation with temozolomide (TMZ) protocol and ready for the maintenance phase of the Stupp protocol with TMZ.

Condition or disease Intervention/treatment Phase
Glioblastoma Device: Focused Ultrasound (FUS) BBB Disruption Not Applicable

Detailed Description:
This is a prospective, single center, single-arm study to establish the safety, feasibility, and effectiveness of BBB disruption along the periphery of the tumor resection cavity using the ExAblate Neuro Model 4000 Type 2 (220 kHz) system and DEFINITY ultrasound contrast in patients with GBM. Adult patients with a first time diagnosis of GBM, whom have undergone maximal safe surgical resection and have safely completed the initial phase of concurrent chemo-radiation therapy, will be recruited for this study. Twenty patients will undergo up to 6 treatments with FUS coincident with their standard TMZ cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
Actual Study Start Date : October 16, 2018
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Focused Ultrasound (FUS) BBB Disruption
The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
Device: Focused Ultrasound (FUS) BBB Disruption
FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
Other Name: Exablate Neuro

Primary Outcome Measures :
  1. Device and procedure related adverse events [ Time Frame: Throughout the study, approximately 12 months. ]
    The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE

Secondary Outcome Measures :
  1. Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging [ Time Frame: Immediately after each FUS BBB disruption procedure ]
    The repeatability of BBB disruption will be evaluated at each of the 6 procedures (coincident with standard of care chemotherapy) and will be evaluated through assessment of post-procedure contrast enhanced MR imaging.

  2. Effectiveness of BBB disruption in the treated tumor region [ Time Frame: at each standard of care neuro-oncology follow up visit until date of death from any cause, assessed up to 48 months ]
    Effectiveness will be assessed based on the MRI characteristics of the FUS treated tumor region as assessed by the modified Response Assessment in Neuro-Oncology Criteria (RANO) to establish GBM status

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men or women.
  2. Age between 18 and 80 years, inclusive.
  3. Able and willing to give informed consent.
  4. Grade IV malignant glioma (GBM) confirmed through assessment of surgical specimens by a board-certified neuropathologist.
  5. Undergone maximal safe surgical resection and completed concurrent radiotherapy+oral TMZ without any complications and deemed eligible for the maintenance phase of TMZ treatment.
  6. Karnofsky rating 70-100.
  7. ASA score 1-3.
  8. Able to communicate during the ExAblate MRgFUS procedure.
  9. Able to attend all study visits (i.e., life expectancy of at least 3 months).

Exclusion Criteria:

  1. Patients presenting with the following imaging characteristics:

    i. Evidence of recent intracranial hemorrhage.

  2. The sonication pathway to the tumour involves:

    i. Extensive scalp scars, ii. Clips or other metallic implanted objects in the skull or the brain (brain implants).

  3. The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).
  4. Patients requiring increasing doses of corticosteroids.
  5. Patient receiving bevacizumab (Avastin) therapy.
  6. Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, and focal irradiation with brachytherapy, stereotactic radiosurgery, and laser interstitial thermotherapy.
  7. Cardiac disease or unstable hemodynamics including:

    i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.

  8. Severe hypertension (diastolic BP > 100 on medication).
  9. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment.
  10. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour hemorrhage.
  11. Documented cerebral infarction within the past 12 months.
  12. TIA in the last 1 month.
  13. Cerebral or systemic vasculopathy.
  14. Insulin-dependent diabetes mellitus that is not well-controlled or that in the Investigator's opinion precludes participation in the study.
  15. Known sensitivity to gadolinium-DTPA.
  16. Known sensitivity to DEFINITY ultrasound contrast agent or perflutren.
  17. Contraindications to MRI such as non-MRI-compatible implanted devices.
  18. Large subjects not fitting comfortably into the MRI scanner.
  19. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
  20. Untreated, uncontrolled sleep apnea.
  21. Positive pregnancy test (for pre-menopausal women).
  22. Known life-threatening systemic disease.
  23. Severely impaired renal function.
  24. Cardiac shunt.
  25. Previous full course of chemotherapy.
  26. Allergy to eggs or egg products.
  27. Subjects with evidence of cranial or systemic infection.
  28. Subjects with chronic pulmonary disorders.
  29. Subjects with a history of drug allergies, asthma or hay fever, and multiple allergies, in particular subjects with a history of anaphylaxis.
  30. Subjects with evidence of Hepatitis B virus infection/carrier state.
  31. Liver injury as indicated by liver function tests.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03616860

Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Nir Lipsman, MD Sunnybrook Health Sciences Centre
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT03616860    
Other Study ID Numbers: BT008C
277981 ( Other Identifier: Health Canada )
First Posted: August 6, 2018    Key Record Dates
Last Update Posted: January 4, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue